AMENDED AND RESTATED ISIS PHARMACEUTICALS, INC. 10B5-1 TRADING PLANIsis Pharmaceuticals Inc • November 5th, 2013 • Pharmaceutical preparations
This Amended and Restated 10b5-1 Trading Plan, (the “Trading Plan”), between ISIS PHARMACEUTICALS, INC. (“Isis”) and INSIGHT SECURITIES, INC. (“Broker”), is entered into effective September 12, 2013 (the “A&R Effective Date”). As of the Effective Date, this Trading Plan amends, restates and supersedes the previous 10b5-1 Trading Plan dated September 13, 2007 between Isis and Broker. Capitalized terms not otherwise defined herein will have the meanings given to them in Exhibit A attached hereto.
AMENDMENT #1 TO COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 5th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #1 TO COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT (this “Amendment”) is entered into as of the date of last signature hereof (the “Amendment Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 (“AstraZeneca”). Isis and AstraZeneca are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
AMENDMENT NUMBER THREE TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 5th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment Number Three (the “Amendment”) to the Amended and Restated License and Collaboration Agreement is entered into as of the 2nd day of August, 2013 (the “Effective Date”) by and among ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”), ISIS PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Isis”, and each of Alnylam and Isis, a “Licensor” and together, the “Licensors”), and REGULUS THERAPEUTICS INC. (formerly Regulus Therapeutics LLC), a Delaware corporation, with its principal place of business at 3545 John Hopkins Court, San Diego, California 92121 (“Regulus”).
STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC.License Agreement • November 5th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 5th day of September, 2013 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and BIOGEN IDEC MA INC., a Massachusetts corporation, having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 (“Biogen Idec”). Biogen Idec and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.
